Rubedo takes cellular rejuvenation into actinic keratosis with early RLS-1496 results
Rubedo’s RLS-1496 shows early actinic keratosis lesion reduction with low irritation. Find out why Phase 2b matters next.
Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market
Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.
Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?
Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.
Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.
Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?
Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.
LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?
LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.
Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?
Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.
Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic
Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Why Galderma is turning ALASTIN into a clinic workflow strategy, not just a skincare brand
Galderma’s ALASTIN Signature Practices aim to embed skincare into aesthetic workflows. Read what this means for clinics, competition, and growth.